RedHill Biopharma Ltd. Announces First Patient Dosed In Phase 3 Study Of RHB-104 For Crohn's Disease
Published: Nov 25, 2013
TEL-AVIV, Israel, Nov. 25, 2013 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"), an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary formulations and combinations of existing drugs, today announced that the first patient has been recruited and dosed in the MAP US study - a Phase III clinical study designed to evaluate the safety and efficacy of fixed-dose RHB-104 in patients with moderately to severely active Crohn's disease.
Help employers find you! Check out all the jobs and post your resume.